Fountain’s $15m to “restore youthful resilience to cells”

Latest articles

Top 10 heath gadgets to live longer and healthier

Top ten health gadgets for the longevity enthusiasts in your life. As the holiday season kicks off with Thanksgiving this year, Christmas is right around...

Eliminating senescent cells in fat can alleviate signs of diabetes

Deleting dysfunctional cells could lead to game-changing treatments for diabetes and other metabolic diseases. Eliminating old, dysfunctional cells in human fat also alleviates signs of...

Longevica: bridging the gap between longevity science and consumers

Longevica CEO sheds further light on work to develop an “open research platform” to drive both longevity science and commercialisation. Following yesterday’s $2.5 million funding...

Longevity Science Summit: care of aging population talks continue

Our dive into Longevity Week's Science Summit continues... Last week, Longevity.Technology was lucky enough to attend Longevity Forum's Science Summit at Oxford's Oriel College, part...

Most read

New supplement slows aging and promotes weight loss

Sugar-proof your way to a longer life. Reducing AGEs to slow aging and increase weight loss – how one supplement is fighting the war...

An antiaging supplement that also reduces appetite?

One for the AGEs: Juvify signs IP licensing deal with Buck Institute for GLYLO antiaging supplement that aims to reduce glycation. A researcher at the...

Resveratrol – the small molecule with big antiaging ideas

When it comes to antiaging molecules, we can learn a thing or two from plants. As so often in natural world, plants have a few...

Editor's picks

Top 10 heath gadgets to live longer and healthier

Top ten health gadgets for the longevity enthusiasts in your life. As the holiday season kicks off with Thanksgiving this year, Christmas is right around...

Eliminating senescent cells in fat can alleviate signs of diabetes

Deleting dysfunctional cells could lead to game-changing treatments for diabetes and other metabolic diseases. Eliminating old, dysfunctional cells in human fat also alleviates signs of...

Longevica: bridging the gap between longevity science and consumers

Longevica CEO sheds further light on work to develop an “open research platform” to drive both longevity science and commercialisation. Following yesterday’s $2.5 million funding...

Click the globe for translations.

Longevity funding: Eli Lilly and R42 Group join the party as Khosla-backed biopharma brings total Series A financing to $26 million.

Longevity biopharma Fountain Therapeutics has secured a $15 million Series A-2 funding round, bringing its total Series A funding to $26 million. The company, which is building a pipeline of disease-modifying therapeutics for chronic degenerative diseases, welcomes new investors Eli Lilly, Alexandria Venture Investments and Ronjon Nag’s R42 Group, joining existing investors Khosla Ventures and Nan Fung Life Sciences.

Longevity.Technology: The science behind Fountain originates from the labs of Stanford professor Thomas Rando – an iconic name in the aging research field. While the company is still playing its cards close to its chest, this significant new funding injection is an indication that positive progress is being made. It’s safe to say we’re watching Fountain’s developments closely.

“Fountain is an example of a biotech company emerging as a direct result of basic research, in this case the biology of aging,” said Dr Rando, founder and chairman of Fountain. “The company’s screening and discovery platform is built upon foundational research showing that the age of a cell can be modulated by factors in the cell’s environment. By identifying compounds that work through these pathways, we seek to restore youthful resilience to cells and tissues, leading to therapies that treat or even prevent chronic diseases of aging.”

New insights generated

Proceeds from the financing will be used to expand Fountain’s cell-based AI-driven technology platform, which is designed to enable precise mapping of cellular biologic age, a marker of resilience and health. The platform enables extraction of cellular features that provide extensive insight into the aging process of cells, which may lead to identification of novel targets and disease biomarkers.

Dr William Greene, who took on the role of CEO at Fountain earlier this year, told us “Fountain is focused on exploring the potential of its AI platform that uses imaging data and machine learning in pre-clinical studies to accurately screen and discover potential therapeutic targets. We have already generated new insights into known targets and potential new disease biology. We will have more updates on this in the future.”

“The scientific framework for our drug discovery technology is based on research showing that the age of a cell can be modulated by factors in the cell’s environment. Therefore, Fountain is exploring a range of potential indications in chronic degenerative diseases with high unmet medical need.”

Fountain
Hard at work in Fountain’s San Francisco lab.

Funding to drive expansion

So how far will this new funding take Fountain, and when can we expect to see the company moving towards clinical trials?

“The funding will be used to support Fountain in its next stage of growth,” Greene tells us. “This includes expansion of our team, continued R&D activities and pre-clinical research. It is too soon to predict when a compound may enter the clinic, but our goal in the next two to three years is to discover potential therapeutics for several chronic degenerative diseases. We are also exploring opportunities to potentially partner with other companies to develop additional promising candidates.”

Greene tells us that he is encouraged by the support Fountain has received from both its existing and new investors, including Eli Lilly, which runs the Gateway Lab space in South San Francisco where Fountain is based.

“The investment from these distinguished institutions supports our mission to increase human health span and provides additional validation for our drug discovery platform,” he says.

“We are excited about Fountain’s AI driven approach to drug discovery and are confident in the team’s ability to build its platform and pipeline,” said Alex Morgan, partner at Khosla Ventures. “Fountain has an opportunity to address several large chronic degenerative diseases associated with aging for multiple indications with high unmet medical need.”

Image courtesy of Dr Thomas Rando
Danny Sullivan
Contributing Editor Danny has worked in technology communications for more than 15 years, spanning Europe and North America. From bionics and lasers to software and pharmaceuticals – and everything in between – he’s covered it all. Danny has wide experience of technology publishing and technical writing and has specific interest in the transfer from idea to market.

Most popular

New supplement slows aging and promotes weight loss

Sugar-proof your way to a longer life. Reducing AGEs to slow aging and increase weight loss – how one supplement is fighting the war...

An antiaging supplement that also reduces appetite?

One for the AGEs: Juvify signs IP licensing deal with Buck Institute for GLYLO antiaging supplement that aims to reduce glycation. A researcher at the...

Resveratrol – the small molecule with big antiaging ideas

When it comes to antiaging molecules, we can learn a thing or two from plants. As so often in natural world, plants have a few...

Tree of Longevity – understanding how supplements work

Pathways? Hallmarks? Biomarkers? Understanding the longevity supplements lingo can help you make better choices for your healthspan. Longevity supplements differ from other 'generic supplements' as...

Related articles

Eliminating senescent cells in fat can alleviate signs of diabetes

Deleting dysfunctional cells could lead to game-changing treatments for diabetes and other metabolic diseases. Eliminating old, dysfunctional cells in human fat also alleviates signs of...

Longevica: bridging the gap between longevity science and consumers

Longevica CEO sheds further light on work to develop an “open research platform” to drive both longevity science and commercialisation. Following yesterday’s $2.5 million funding...

Young blood: discover the possibilities of plasma based therapy

The evolution of plasma-based therapeutics is accelerating – our FREE report cuts through the young blood hype for the lowdown on the latest therapies. Our...

Longevica raises $2.5 million for open research platform

$2.5m in funding to support longevity research platform and study to accelerate the discovery of life extension mechanisms, launching in 2022. Longevica, a life science...

A global perspective on consumer longevity data

WHO head of aging and health to present at ARK event focused on the importance of data in the quest for improved longevity. Tomorrow is...

    Subscribe to our newsletter